nefrНефрологияNephrology (Saint-Petersburg)1561-62742541-9439Pavlov First Saint-Petersburg State Medical Universitynefr-187Research ArticleПЕРЕДОВАЯ СТАТЬЯLEADING ARTICLEФосфат, почки, кости и сердечно-сосудистая системаPhosphate, kidneys, bones and cardiovascular systemДобронравовВладимир АлександровичDobronravovVladimir A.dobronravov@nepbrolog.ruНаучно-исследовательский институт нефрологии Санкт-Петербургского государственного медицинского университета им. акад. И.П. ПавловаРоссияResearch Institute of Nephrology, First Pavlov Saint-Petersburg State Medical UniversityRussian Federation2016010720162041024Copyright © Добронравов В.А., 20162016Добронравов В.А.Dobronravov V.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://journal.nephrolog.ru/jour/article/view/187

Исследования последнего времени позволили установить отчетливую связь между уровнем неорганического фосфата (Pi) сыворотки крови, нарушением баланса эндокринных и паракринных систем, регулирующих обмен Pi, с фатальными и нефатальными сердечно-сосудистыми событиями. Данные связи продемонстрированы как для больных с хронической болезнью почек (ХБП), так и для общей популяции. В рамках концепции обсуждаются клинические и экспериментальные данные в рамках концепции, объединяющей патофизиологию нарушений обмена Pi, типичных для ХБП, и развитие изменений в сердечно-сосудистой системе.

Recent studies have clearly linked higher serum inorganic phosphate (Pi) concentrations and an imbalance of Pi-regulating kidney-bone-parathyroid endocrine and paracrine systems to cardiovascular disease (CVD) events and mortality. This association has been identified in patients with chronic kidney disease (CKD) and in the general population. This editorial discusses the available clinical and experimental data in frames of the conception linking pathophysiology of phosphate exchange disorders related to CKD and CVD events.

неорганический фосфатхроническая болезнь почекизменения сердечно-сосудистой системысердечно-сосудистые рискиinorganic phosphatechronic kidney diseasedisorders of cardiovascular systemcardiovascular risksReferencesKestenbaum B, Sampson JN, Rudser KD et al. Serum phosphate levels and mortality risk among people with chronic kidney disease. J Am Soc Nephrol 2005; 16: 520-528. doi: 10.1681/ASN.2004070602Kestenbaum B, Sampson JN, Rudser KD et al. Serum phosphate levels and mortality risk among people with chronic kidney disease. J Am Soc Nephrol 2005; 16: 520-528. doi: 10.1681/ASN.2004070602McGovern AP, De Lusignan S, Van Vlymen J et al. Serum phosphate as a risk factor for cardiovascular events in people with and without chronic kidney disease: a large community based cohort study. PLoS One. 2013; 8(9): 74996. doi: 10.1371/journal.pone.0074996McGovern AP, De Lusignan S, Van Vlymen J et al. Serum phosphate as a risk factor for cardiovascular events in people with and without chronic kidney disease: a large community based cohort study. PLoS One. 2013; 8(9): 74996. doi: 10.1371/journal.pone.0074996Kendrick J, Kestenbaum В, Chonchol М. Phosphate and Cardiovascular Disease. Adv Chronic Kidney Dis 2011; 18(2): 113-119. doi: 10.1053/j.ackd.2010.12.003Kendrick J, Kestenbaum В, Chonchol М. Phosphate and Cardiovascular Disease. Adv Chronic Kidney Dis 2011; 18(2): 113-119. doi: 10.1053/j.ackd.2010.12.003Смирнов АВ, Шилов ЕМ, Добронравов ВА. и др. Национальные рекомендации. Хроническая болезнь почек: основные принципы скрининга, диагностики, профилактики и подходы к лечению. Нефрология. 2012; 16(1): 89 -115 [Smirnov AV, Shilov EM, Dobronravov VA i dr. Nacional’nye rekomendacii. Hronicheskaya bolezn’ pochek: osnovnye principy skrininga, diagnostiki, profilaktiki i podhody k lecheniyu Nacional’nye rekomendacii. Nefrologiya 2012; 16(1): 89 -115]Смирнов АВ, Шилов ЕМ, Добронравов ВА. и др. Национальные рекомендации. Хроническая болезнь почек: основные принципы скрининга, диагностики, профилактики и подходы к лечению. Нефрология. 2012; 16(1): 89 -115 [Smirnov AV, Shilov EM, Dobronravov VA i dr. Nacional’nye rekomendacii. Hronicheskaya bolezn’ pochek: osnovnye principy skrininga, diagnostiki, profilaktiki i podhody k lecheniyu Nacional’nye rekomendacii. Nefrologiya 2012; 16(1): 89 -115]Blacher J, Asmar R, Djane S et al. Aortic pulse wave velocity as a marker of cardiovascular risk in hypertensive patients. Hypertension 1999; 33(5): 1111-1117. doi: 10.1161/01.HYP.33.5.1111Blacher J, Asmar R, Djane S et al. Aortic pulse wave velocity as a marker of cardiovascular risk in hypertensive patients. Hypertension 1999; 33(5): 1111-1117. doi: 10.1161/01.HYP.33.5.1111Hollander M, Hak AE, Koudstaal PJ et al. Comparison between measures of atherosclerosis and risk of stroke: the Rotterdam Study. Stroke 2003; 34(10): 2367-2372. doi: 10.1161/01.STR.0000091393.32060.0EHollander M, Hak AE, Koudstaal PJ et al. Comparison between measures of atherosclerosis and risk of stroke: the Rotterdam Study. Stroke 2003; 34(10): 2367-2372. doi: 10.1161/01.STR.0000091393.32060.0EDetrano R, Guerci AD, Carr JJ et al. Coronary calcium as a predictor of coronary events in four racial or ethnic groups. N Engl J Med 2008; 358: 1336-1345. doi: 10.1056/NEJMoa072100Detrano R, Guerci AD, Carr JJ et al. Coronary calcium as a predictor of coronary events in four racial or ethnic groups. N Engl J Med 2008; 358: 1336-1345. doi: 10.1056/NEJMoa072100Olson JC, Edmundowicz D, Becker DJ et al. Coronary calcium in adults with type 1 diabetes: a stronger correlate of clinical coronary artery disease in men than in women. Diabetes 2000; 49: 1571-1578Olson JC, Edmundowicz D, Becker DJ et al. Coronary calcium in adults with type 1 diabetes: a stronger correlate of clinical coronary artery disease in men than in women. Diabetes 2000; 49: 1571-1578London GM, Guerin AP, Marchais SJ et al. Arterial media calcification in end -stage renal disease: impact on all -cause and cardiovascular mortality. Nephrol Dial Transplant 2003; 18: 1731-1740London GM, Guerin AP, Marchais SJ et al. Arterial media calcification in end -stage renal disease: impact on all -cause and cardiovascular mortality. Nephrol Dial Transplant 2003; 18: 1731-1740Klassen PS, Lowrie EG, Reddan DN et al. Association between pulse pressure and mortality in patients undergoing maintenance hemodialysis. JAMA 2002; 287: 1548-1555.Klassen PS, Lowrie EG, Reddan DN et al. Association between pulse pressure and mortality in patients undergoing maintenance hemodialysis. JAMA 2002; 287: 1548-1555.Hunt JL, Fairman R, Mitchell ME et al. Bone formation in carotid plaques: a clinicopathological study. Stroke 2002; 33: 1214-1219Hunt JL, Fairman R, Mitchell ME et al. Bone formation in carotid plaques: a clinicopathological study. Stroke 2002; 33: 1214-1219Edmonds ME, Morrison N, Laws JW et al. Medial arterial calcification and diabetic neuropathy. Br Med J (Clin Res Ed) 1982; 284: 928-930Edmonds ME, Morrison N, Laws JW et al. Medial arterial calcification and diabetic neuropathy. Br Med J (Clin Res Ed) 1982; 284: 928-930Micheletti RG, Fishbein GA, Currier JS et al. Monckeberg sclerosis revisited: a clarification of the histologic definition of Monckeberg sclerosis. Arch Pathol Lab Med 2008; 132: 43-47. doi: 10.2215/CJN.01930408Micheletti RG, Fishbein GA, Currier JS et al. Monckeberg sclerosis revisited: a clarification of the histologic definition of Monckeberg sclerosis. Arch Pathol Lab Med 2008; 132: 43-47. doi: 10.2215/CJN.01930408Goodman WG, Goldin J, Kuizon BD et al. Coronary -artery calcification in young adults with end -stage renal disease who are undergoing dialysis. N Engl J Med 2000; 342: 1478-1483Goodman WG, Goldin J, Kuizon BD et al. Coronary -artery calcification in young adults with end -stage renal disease who are undergoing dialysis. N Engl J Med 2000; 342: 1478-1483Ix JH, De Boer IH, Peralta CA et al. Serum phosphorus concentrations and arterial stiffness among individuals with normal kidney function to moderate kidney disease in MESA. Clin J Am Soc Nephrol 2009; 4: 609-615. doi: 10.2215/CJN.04100808Ix JH, De Boer IH, Peralta CA et al. Serum phosphorus concentrations and arterial stiffness among individuals with normal kidney function to moderate kidney disease in MESA. Clin J Am Soc Nephrol 2009; 4: 609-615. doi: 10.2215/CJN.04100808Foley RN, Collins AJ, Herzog CA et al. Serum phosphorus levels associate with coronary atherosclerosis in young adults. J Am Soc Nephrol. 2009; 20: 397-404. doi: 10.1681/ASN.2008020141Foley RN, Collins AJ, Herzog CA et al. Serum phosphorus levels associate with coronary atherosclerosis in young adults. J Am Soc Nephrol. 2009; 20: 397-404. doi: 10.1681/ASN.2008020141Kendrick J, Ix JH, Targher G et al. Relation of serum phosphorus levels to ankle brachial pressure index (from the Third National Health and Nutrition Examination Survey). Am J Cardiol 2010; 106(4): 564-568. doi: 10.1016/j.amjcard.2010.03.070Kendrick J, Ix JH, Targher G et al. Relation of serum phosphorus levels to ankle brachial pressure index (from the Third National Health and Nutrition Examination Survey). Am J Cardiol 2010; 106(4): 564-568. doi: 10.1016/j.amjcard.2010.03.070Li JW, Xu C, Fan Y et al. Can serum levels of alkaline phosphatase and phosphate predict cardiovascular diseases and total mortality in individuals with preserved renal function? A systemic review and meta-analysis. PLoS One 2014; 9(7): e102276. doi: 10.1371/journal.pone.0102276Li JW, Xu C, Fan Y et al. Can serum levels of alkaline phosphatase and phosphate predict cardiovascular diseases and total mortality in individuals with preserved renal function? A systemic review and meta-analysis. PLoS One 2014; 9(7): e102276. doi: 10.1371/journal.pone.0102276Strozecki P, Adamowicz A, Nartowicz E et al. Parathormone, calcium, phosphorus, and left ventricular structure and function in normotensive hemodialysis patients. Ren Fail 2001; 23: 115-126Strozecki P, Adamowicz A, Nartowicz E et al. Parathormone, calcium, phosphorus, and left ventricular structure and function in normotensive hemodialysis patients. Ren Fail 2001; 23: 115-126Galetta F, Cupisti A, Franzoni F et al. Changes in heart rate variability in chronic uremic patients during ultrafiltration and hemodialysis. Blood Purif 2001; 19: 395-400Galetta F, Cupisti A, Franzoni F et al. Changes in heart rate variability in chronic uremic patients during ultrafiltration and hemodialysis. Blood Purif 2001; 19: 395-400Culleton BF, Walsh M, Karenbach SW et al. Effect of frequent nocturnal hemodialysis vs conventional hemodialysis on left ventricular mass and quality of life: a randomized controlled trial. JAMA 2007; 298: 1291-1299. doi: 10.1001/jama.298.11.1291Culleton BF, Walsh M, Karenbach SW et al. Effect of frequent nocturnal hemodialysis vs conventional hemodialysis on left ventricular mass and quality of life: a randomized controlled trial. JAMA 2007; 298: 1291-1299. doi: 10.1001/jama.298.11.1291Yamamoto KT, Robinson-Cohen C, De Oliveira MC et al. Dietary phosphorus is associated with greater left ventricular mass. Kidney Int 2013; 83(4): 707-714. doi: 10.1038/ki.2012.303Yamamoto KT, Robinson-Cohen C, De Oliveira MC et al. Dietary phosphorus is associated with greater left ventricular mass. Kidney Int 2013; 83(4): 707-714. doi: 10.1038/ki.2012.303Slinin Y, Foley RN, Collins AJ. Calcium, phosphorus, parathyroid hormone and cardiovascular disease in hemodialysis patients. The USRDS waves 1,3, and 4 study. J Am Soc Nephrol 2005; 16: 1788-1793Slinin Y, Foley RN, Collins AJ. Calcium, phosphorus, parathyroid hormone and cardiovascular disease in hemodialysis patients. The USRDS waves 1,3, and 4 study. J Am Soc Nephrol 2005; 16: 1788-1793Block GA, Klassen PS, Lazarus JM et al. Mineral metabolism, mortality, and morbidity in hemodialysis patients. J Am Soc Nephrol. 2004; 15: 2208-2218Block GA, Klassen PS, Lazarus JM et al. Mineral metabolism, mortality, and morbidity in hemodialysis patients. J Am Soc Nephrol. 2004; 15: 2208-2218Chonchol M, Dale R, Schrier RW, Estacio R. Serum phosphorus and cardiovascular mortality in type 2 diabetes. Am J Med. 2009; 122: 380-386. doi: 10.1016/j.amjmed.2008.09.039Chonchol M, Dale R, Schrier RW, Estacio R. Serum phosphorus and cardiovascular mortality in type 2 diabetes. Am J Med. 2009; 122: 380-386. doi: 10.1016/j.amjmed.2008.09.039Tonelli M, Sacks F, Pfeffer M et al. Relation between serum phosphate level and cardiovascular event rate in people with coronary disease. Circulation. 2005; 112: 2627-2633Tonelli M, Sacks F, Pfeffer M et al. Relation between serum phosphate level and cardiovascular event rate in people with coronary disease. Circulation. 2005; 112: 2627-2633Dhingra R, Sullivan LM, Fox CS et al. Relations of serum phosphorus and calcium levels to the incidence of cardiovascular disease in the community. Arch Intern Med. 2007; 167: 879-885Dhingra R, Sullivan LM, Fox CS et al. Relations of serum phosphorus and calcium levels to the incidence of cardiovascular disease in the community. Arch Intern Med. 2007; 167: 879-885Foley RN, Collins AJ, Ishani A, Kalra PA. Calcium-phosphate levels and cardiovascular disease in community-swelling adults: The Atherosclerosis Risk in Communities (ARIC) Study. Am Heart J. 2008; 156: 556-563. doi: 10.1016/j.ahj.2008.05.016Foley RN, Collins AJ, Ishani A, Kalra PA. Calcium-phosphate levels and cardiovascular disease in community-swelling adults: The Atherosclerosis Risk in Communities (ARIC) Study. Am Heart J. 2008; 156: 556-563. doi: 10.1016/j.ahj.2008.05.016Li JW, Xu C, Fan Y, Wang Y et al. Can serum levels of alkaline phosphatase and phosphate predict cardiovascular diseases and total mortality in individuals with preserved renal function? A systemic review and meta-analysis. PLoS One. 2014; 9(7): e102276. doi: 10.1371/journal.pone.0102276Li JW, Xu C, Fan Y, Wang Y et al. Can serum levels of alkaline phosphatase and phosphate predict cardiovascular diseases and total mortality in individuals with preserved renal function? A systemic review and meta-analysis. PLoS One. 2014; 9(7): e102276. doi: 10.1371/journal.pone.0102276Palmer SC, Hayen A, Macaskill P et al. Serum levels of phosphorus, parathyroid hormone, and calcium and risks of death and cardiovascular disease in individuals with chronic kidney disease: a systematic review and meta-analysis. J Am Med Assoc. 2011; 305: 1119-1127. doi: 10.1001/jama.2011.308Palmer SC, Hayen A, Macaskill P et al. Serum levels of phosphorus, parathyroid hormone, and calcium and risks of death and cardiovascular disease in individuals with chronic kidney disease: a systematic review and meta-analysis. J Am Med Assoc. 2011; 305: 1119-1127. doi: 10.1001/jama.2011.308Добронравов ВА. Современный взгляд на патофизиологию вторичного гиперпаратиреоза: роль фактора роста фибробластов 23 и klotho. Нефрология. 2011; 15(4): 11-20 [Dobronravov VA. Sovremennyj vzglyad na patofiziologiyu vtorichnogo giperparatireoza: rol’ faktora rosta fibroblastov 23 i klotho. Nefrologiya. 2011; 15(4): 11-20]Добронравов ВА. Современный взгляд на патофизиологию вторичного гиперпаратиреоза: роль фактора роста фибробластов 23 и klotho. Нефрология. 2011; 15(4): 11-20 [Dobronravov VA. Sovremennyj vzglyad na patofiziologiyu vtorichnogo giperparatireoza: rol’ faktora rosta fibroblastov 23 i klotho. Nefrologiya. 2011; 15(4): 11-20]Милованова ЛЮ, Козловская ЛВ, Милованов ЮС, и др. Механизмы нарушения фосфорно-кальциевого гомеостаза в развитии сердечно-сосудистых осложнений у больных хронической болезнью почек. Роль фактора роста фибробластов-23 (fgf-23) и klotho. Терапевтический архив. 2010; 82 (6): 66-72 [Milovanova LYu, Kozlovskaya LV, MilovanovYuS, i dr. Mekhanizmy narusheniya fosforno-kal’cievogo gomeostaza v razvitii serdechno-sosudistyh oslozhnenij u bol’nyh hronicheskoj bolezn’yu pochek. rol’ faktora rosta fibroblastov-23 (fgf-23) i klotho. Terapevticheskij arhiv. 2010; 82 (6): 66-72].Милованова ЛЮ, Козловская ЛВ, Милованов ЮС, и др. Механизмы нарушения фосфорно-кальциевого гомеостаза в развитии сердечно-сосудистых осложнений у больных хронической болезнью почек. Роль фактора роста фибробластов-23 (fgf-23) и klotho. Терапевтический архив. 2010; 82 (6): 66-72 [Milovanova LYu, Kozlovskaya LV, MilovanovYuS, i dr. Mekhanizmy narusheniya fosforno-kal’cievogo gomeostaza v razvitii serdechno-sosudistyh oslozhnenij u bol’nyh hronicheskoj bolezn’yu pochek. rol’ faktora rosta fibroblastov-23 (fgf-23) i klotho. Terapevticheskij arhiv. 2010; 82 (6): 66-72].Kuro -o M. Klotho, phosphate and FGF -23 in ageing and disturbed mineral metabolism. Nat Rev Nephrol 2013; 9: 650-660. doi: 10.1038/nrneph.2013.111Kuro -o M. Klotho, phosphate and FGF -23 in ageing and disturbed mineral metabolism. Nat Rev Nephrol 2013; 9: 650-660. doi: 10.1038/nrneph.2013.111Dobronravov V, Kaukov I, Smirnov A. Dietary protein intake i s independently associated with the urinary excretion of phosphate. Kidney Res and Clin Practice. 2012; 31(2): A28-A29. doi: 10.1016/j.krcp.2012.04.374Dobronravov V, Kaukov I, Smirnov A. Dietary protein intake i s independently associated with the urinary excretion of phosphate. Kidney Res and Clin Practice. 2012; 31(2): A28-A29. doi: 10.1016/j.krcp.2012.04.374Isakova T, Xie H, Yang W et al. Chronic Renal Insufficiency Cohort (CRIC) Study Group : Fibroblast growth factor 23 and risks of mortality and end - stage renal disease in patients with chronic kidney disease. JAMA 2011; 305: 2432-2439. doi: 10.1001/jama.2011.826Isakova T, Xie H, Yang W et al. Chronic Renal Insufficiency Cohort (CRIC) Study Group : Fibroblast growth factor 23 and risks of mortality and end - stage renal disease in patients with chronic kidney disease. JAMA 2011; 305: 2432-2439. doi: 10.1001/jama.2011.826Pavik I, Jaeger P, Ebner L. Secreted Klotho and FGF23 in chronic kidney disease Stage 1 to 5: a sequence suggested from a cross-sectional study. Nephrol Dial Transplant 2013; 28(2): 352359. doi: 10.1093/ndt/gfs460Pavik I, Jaeger P, Ebner L. Secreted Klotho and FGF23 in chronic kidney disease Stage 1 to 5: a sequence suggested from a cross-sectional study. Nephrol Dial Transplant 2013; 28(2): 352359. doi: 10.1093/ndt/gfs460Barker SL, Pastor J, Carranza D et al. The demonstration of αKlotho deficiency in human chronic kidney disease with a novel synthetic antibody. Nephrol Dial Transplant 2015 ; 30(2): 223-233. doi: 10.1093/ndt/gfu291.Barker SL, Pastor J, Carranza D et al. The demonstration of αKlotho deficiency in human chronic kidney disease with a novel synthetic antibody. Nephrol Dial Transplant 2015 ; 30(2): 223-233. doi: 10.1093/ndt/gfu291.Богданова ЕО, Галкина ОВ, Зубина ИМ, Добронравов ВА. Klotho, фактор роста фибробластов 23 и неорганический фосфат на ранних стадиях хронической болезни почек. Нефрология. 2016; 4: 53-60 [Bogdanova EO, Galkina OV, Zubina IM, Dobronravov VA. Klotho, faktor rosta fibroblastov 23 i neorganicheskij fosfat na rannih stadiyah hronicheskoj bolezni pochek. Nefrologiya. 2016; 4: 53-60]Богданова ЕО, Галкина ОВ, Зубина ИМ, Добронравов ВА. Klotho, фактор роста фибробластов 23 и неорганический фосфат на ранних стадиях хронической болезни почек. Нефрология. 2016; 4: 53-60 [Bogdanova EO, Galkina OV, Zubina IM, Dobronravov VA. Klotho, faktor rosta fibroblastov 23 i neorganicheskij fosfat na rannih stadiyah hronicheskoj bolezni pochek. Nefrologiya. 2016; 4: 53-60]Schiavi SC, Tang W, Bracken C et al. Npt2b deletion attenuates hyperphosphatemia associated with CKD. J Am Soc Nephrol. 2012; 23: 1691-1700. doi: 10.1681/ASN.2011121213Schiavi SC, Tang W, Bracken C et al. Npt2b deletion attenuates hyperphosphatemia associated with CKD. J Am Soc Nephrol. 2012; 23: 1691-1700. doi: 10.1681/ASN.2011121213Takeda E, Yamamoto H, Yamanaka-Okumura H, Taketani Y. Dietary phosphorus in bone health and quality of life. Nutr Rev. 2012; 70: 311-321. doi: 10.1111/j.1753-4887.2012.00473.xTakeda E, Yamamoto H, Yamanaka-Okumura H, Taketani Y. Dietary phosphorus in bone health and quality of life. Nutr Rev. 2012; 70: 311-321. doi: 10.1111/j.1753-4887.2012.00473.xKarp HJ, Kemi VE, Lamberg-Allardt CJ, Karkkainen MU. Mono- and polyphosphates have similar effects on calcium and phosphorus metabolism in healthy young women. Eur J Nutr. 2013; 52: 991-996. doi: 10.1007/s00394-012-0406-5Karp HJ, Kemi VE, Lamberg-Allardt CJ, Karkkainen MU. Mono- and polyphosphates have similar effects on calcium and phosphorus metabolism in healthy young women. Eur J Nutr. 2013; 52: 991-996. doi: 10.1007/s00394-012-0406-5London GM et al. Arterial calcifications and bone histomorphometry in end-stage renal disease. J Am Soc Nephrol. 2004; 15: 1943-51. doi: 10.1097/01.ASN.0000129337.50739.48London GM et al. Arterial calcifications and bone histomorphometry in end-stage renal disease. J Am Soc Nephrol. 2004; 15: 1943-51. doi: 10.1097/01.ASN.0000129337.50739.48Ferreira JC, Ferrari GO, Neves KR et al. Effects of dietary phosphate on adynamic bone disease in rats with chronic kidney diseaserole of sclerostin? PLoS One. 2013; 8(11): e79721. doi: 10.1371/journal.pone.0079721Ferreira JC, Ferrari GO, Neves KR et al. Effects of dietary phosphate on adynamic bone disease in rats with chronic kidney diseaserole of sclerostin? PLoS One. 2013; 8(11): e79721. doi: 10.1371/journal.pone.0079721Pereira RC, Juppner H, Azucena-Serrano CE et al. Patterns of FGF-23, DMP1, and MEPE expression in patients with chronic kidney disease. Bone. 2009; 45: 1161-68. doi: 10.1016/j.bone.2009.08.008Pereira RC, Juppner H, Azucena-Serrano CE et al. Patterns of FGF-23, DMP1, and MEPE expression in patients with chronic kidney disease. Bone. 2009; 45: 1161-68. doi: 10.1016/j.bone.2009.08.008Drüeke TB, Massy ZA.Changing bone patterns with progression of chronic kidney disease. Kidney Int. 2016; 89(2): 289-302. doi: 10.1016/j.kint.2015.12.004Drüeke TB, Massy ZA.Changing bone patterns with progression of chronic kidney disease. Kidney Int. 2016; 89(2): 289-302. doi: 10.1016/j.kint.2015.12.004Rendenbach C, Yorgan TA, Heckt T et al. Effects of extracellular phosphate on gene expression in murine osteoblasts. Calcif Tissue Int. 2014; 94(5): 474-483. doi: 10.1007/s00223-013-9831-6Rendenbach C, Yorgan TA, Heckt T et al. Effects of extracellular phosphate on gene expression in murine osteoblasts. Calcif Tissue Int. 2014; 94(5): 474-483. doi: 10.1007/s00223-013-9831-6Ito N, Findlay DM, Anderson PH et al. Extracellular phosphate modulates the effect of 1α, 25-dihydroxy vitamin D3 (1,25D) on osteocyte like cells. J Steroid Biochem Mol Biol. 2013; 136: 183. doi: 10.1016/j.jsbmb.2012.09.029Ito N, Findlay DM, Anderson PH et al. Extracellular phosphate modulates the effect of 1α, 25-dihydroxy vitamin D3 (1,25D) on osteocyte like cells. J Steroid Biochem Mol Biol. 2013; 136: 183. doi: 10.1016/j.jsbmb.2012.09.029Bellido T, Plotkin LI. Novel actions of bisphosphonates in bone: Preservation of osteoblast and osteocyte viability. Bone. 2011; 49: 50-55. doi: 10.1016/j.bone.2010.08.008Bellido T, Plotkin LI. Novel actions of bisphosphonates in bone: Preservation of osteoblast and osteocyte viability. Bone. 2011; 49: 50-55. doi: 10.1016/j.bone.2010.08.008Prideaux M, Loveridge N, Pitsillides AA, Farquharson C. Extracellular matrix mineralization promotes E11/gp38 glycoprotein expression and drives osteocytic differentiation. PLoS One. 2012; 7(5): e36786. doi: 10.1371/journal.pone.0036786.Prideaux M, Loveridge N, Pitsillides AA, Farquharson C. Extracellular matrix mineralization promotes E11/gp38 glycoprotein expression and drives osteocytic differentiation. PLoS One. 2012; 7(5): e36786. doi: 10.1371/journal.pone.0036786.Bonewald LF. The amazing osteocyte. J of Bone and Mineral Res. 2011; 26(2): 229-238. doi: 10.1002/jbmr.320Bonewald LF. The amazing osteocyte. J of Bone and Mineral Res. 2011; 26(2): 229-238. doi: 10.1002/jbmr.320Plotkin LI, Mathov I, Aguirre JI et al. Mechanical stimulation prevents osteocyte apoptosis: requirement of integrins, Src kinases and ERKs. Am J Physiol Cell Physiol. 2005; 289: 633-C643Plotkin LI, Mathov I, Aguirre JI et al. Mechanical stimulation prevents osteocyte apoptosis: requirement of integrins, Src kinases and ERKs. Am J Physiol Cell Physiol. 2005; 289: 633-C643Tsuji K, Bandyopadhyay A, Harfe BD et al. BMP2 activity, although dispensable for bone formation, is required for the initiation of fracture healing. Nat Genet. 2006; 38: 1424-1429Tsuji K, Bandyopadhyay A, Harfe BD et al. BMP2 activity, although dispensable for bone formation, is required for the initiation of fracture healing. Nat Genet. 2006; 38: 1424-1429Hu H, Hilton MJ, Tu X et al. Sequential roles of Hedgehog and Wnt signaling in osteoblast development. Development. 2005; 132: 49-60Hu H, Hilton MJ, Tu X et al. Sequential roles of Hedgehog and Wnt signaling in osteoblast development. Development. 2005; 132: 49-60Karsenty G, Kronenberg HM, Settembre C. Genetic control of bone formation. Annu Rev Cell Dev Biol. 2009; 25: 629-648. doi: 10.1146/annurev.cellbio.042308.113308Karsenty G, Kronenberg HM, Settembre C. Genetic control of bone formation. Annu Rev Cell Dev Biol. 2009; 25: 629-648. doi: 10.1146/annurev.cellbio.042308.113308Satokata I, Ma L, Ohshima H et al. Msx2 deficiency in mice causes pleiotropic defects in bone growth and ectodermal organ formation. Nat Genet. 2000; 24: 391-395Satokata I, Ma L, Ohshima H et al. Msx2 deficiency in mice causes pleiotropic defects in bone growth and ectodermal organ formation. Nat Genet. 2000; 24: 391-395Koga T, Matsui Y, Asagiri M et al. NFAT and Osterix cooperatively regulate bone formation. Nat Med. 2005; 11: 880-885.Koga T, Matsui Y, Asagiri M et al. NFAT and Osterix cooperatively regulate bone formation. Nat Med. 2005; 11: 880-885.Canalis E. Update in new anabolic therapies for osteoporosis. J Clin Endocrinol Metab. 2010; 95: 1496-1504. doi: 10.1210/ jc.2009-2677Canalis E. Update in new anabolic therapies for osteoporosis. J Clin Endocrinol Metab. 2010; 95: 1496-1504. doi: 10.1210/ jc.2009-2677Смирнов АВ, Румянцев АШ. Строение и функции костной ткани в норме и при патологии. Сообщение II. Нефрология. 2015; 19(1): 8-17 [Smirnov AV, Rumyancev ASh. Stroenie i funkcii kostnoj tkani v norme i pri patologii. Soobshchenie II. Nefrologiya. 2015; 19(1): 8-17].Смирнов АВ, Румянцев АШ. Строение и функции костной ткани в норме и при патологии. Сообщение II. Нефрология. 2015; 19(1): 8-17 [Smirnov AV, Rumyancev ASh. Stroenie i funkcii kostnoj tkani v norme i pri patologii. Soobshchenie II. Nefrologiya. 2015; 19(1): 8-17].Sabbagh Y Graciolli FG, O’Brien S et al. Repression of osteocyte Wnt/S-catenin signaling is an early event in the progression of renal osteodystrophy. J Bone Miner Res. 2012; 27: 1757-1772. doi: 10.1002/jbmr. 1630Sabbagh Y Graciolli FG, O’Brien S et al. Repression of osteocyte Wnt/S-catenin signaling is an early event in the progression of renal osteodystrophy. J Bone Miner Res. 2012; 27: 1757-1772. doi: 10.1002/jbmr. 1630Rowe PS. Regulation of bone-renal mineral and energy metabolism: the PHEX, FGF23, DMP1, MEPE ASARM pathway. Crit Rev Eukaryot Gene Expr. 2012; 22(1): 61-86Rowe PS. Regulation of bone-renal mineral and energy metabolism: the PHEX, FGF23, DMP1, MEPE ASARM pathway. Crit Rev Eukaryot Gene Expr. 2012; 22(1): 61-86David V, Martin A, Hedge AM. ASARM peptides: PHEX-dependent and -independent regulation of serum phosphate. Am J Physiol Renal Physiol. 2011; 300(3): 783-791David V, Martin A, Hedge AM. ASARM peptides: PHEX-dependent and -independent regulation of serum phosphate. Am J Physiol Renal Physiol. 2011; 300(3): 783-791Evenepoel P, D’Haese P, Brandenburg V. Sclerostin and DKK1: new players in renal bone and vascular disease. Kidney Int. 2015 Aug; 88(2): 235-240. doi: 10.1038/ki.2015.156Evenepoel P, D’Haese P, Brandenburg V. Sclerostin and DKK1: new players in renal bone and vascular disease. Kidney Int. 2015 Aug; 88(2): 235-240. doi: 10.1038/ki.2015.156Confavreux CB. Bone: from a reservoir of minerals to a regulator of energy metabolism. Kidney International. 2011; 79(121): 14-19. doi: 10.1038/ki.2011.25Confavreux CB. Bone: from a reservoir of minerals to a regulator of energy metabolism. Kidney International. 2011; 79(121): 14-19. doi: 10.1038/ki.2011.25Kurz P, Monier-Faugere MC, Bognar B et al. Evidence for abnormal calcium homeostasis in patients with adynamic bone disease. Kidney Int. 1994; 46: 855-861Kurz P, Monier-Faugere MC, Bognar B et al. Evidence for abnormal calcium homeostasis in patients with adynamic bone disease. Kidney Int. 1994; 46: 855-861Sage AP, Lu J, Tintut Yet al. Hyperphosphatemia -induced nanocrystals upregulate the expression of bone morphogenetic protein-2 and osteopontin genes in mouse smooth muscle cells in vitro. Kidney Int. 2011; 79: 414-422. doi: 10.1038/ki.2010.390Sage AP, Lu J, Tintut Yet al. Hyperphosphatemia -induced nanocrystals upregulate the expression of bone morphogenetic protein-2 and osteopontin genes in mouse smooth muscle cells in vitro. Kidney Int. 2011; 79: 414-422. doi: 10.1038/ki.2010.390Villa-Bellosta R, Sorribas V. Phosphonoformic acid prevents vascular smooth muscle cell calcification by inhibiting calcium - phosphate deposition. Arterioscler Thromb Vasc Biol. 2009; 29: 761-766. doi: 10.1161/ATVBAHA.108.183384Villa-Bellosta R, Sorribas V. Phosphonoformic acid prevents vascular smooth muscle cell calcification by inhibiting calcium - phosphate deposition. Arterioscler Thromb Vasc Biol. 2009; 29: 761-766. doi: 10.1161/ATVBAHA.108.183384Ewence AE, Bootman M, Roderick HL et al. Calcium phosphate crystals induce cell death in human vascular smooth muscle cells: a potential mechanism in atherosclerotic plaque destabilization. Circ Res. 2008; 103: e28-e34. doi: 10.1161/CIRCRESAHA.108.181305Ewence AE, Bootman M, Roderick HL et al. Calcium phosphate crystals induce cell death in human vascular smooth muscle cells: a potential mechanism in atherosclerotic plaque destabilization. Circ Res. 2008; 103: e28-e34. doi: 10.1161/CIRCRESAHA.108.181305Smith ER, Ford ML, Tomlinson LA et al. Phosphorylated fetuin-A-containing calciprotein particles are associated with aortic stiffness and a procalcific milieu in patients with pre-dialysis CKD. Nephrol Dial Transplant. 2012; 27(5): 1957 -1966. doi: 10.1093/ ndt/gfr609Smith ER, Ford ML, Tomlinson LA et al. Phosphorylated fetuin-A-containing calciprotein particles are associated with aortic stiffness and a procalcific milieu in patients with pre-dialysis CKD. Nephrol Dial Transplant. 2012; 27(5): 1957 -1966. doi: 10.1093/ ndt/gfr609Abbasian N, Burton JO, Herbert KE et al. Hyperphosphatemia, phosphoprotein phosphatases, and microparticle release in vascular endothelial cells. J Am Soc Nephrol. 2015; 26: 2152-2162. doi: 10.1681/ASN.2014070642Abbasian N, Burton JO, Herbert KE et al. Hyperphosphatemia, phosphoprotein phosphatases, and microparticle release in vascular endothelial cells. J Am Soc Nephrol. 2015; 26: 2152-2162. doi: 10.1681/ASN.2014070642Chavkin NW, Chia JJ, Crouthamel MH, Giachelli CM. Phosphate uptake-independent signaling functions of the type III sodium-dependent phosphate transporter, PiT-1, in vascular smooth muscle cells. Exp Cell Res. 2015; 333(1): 39-48. doi: 10.1016/j.yexcr.2015.02.00Chavkin NW, Chia JJ, Crouthamel MH, Giachelli CM. Phosphate uptake-independent signaling functions of the type III sodium-dependent phosphate transporter, PiT-1, in vascular smooth muscle cells. Exp Cell Res. 2015; 333(1): 39-48. doi: 10.1016/j.yexcr.2015.02.00Steitz SA, Speer MY, Curinga G et al. Smooth muscle cell phenotypic transition associated with calcification: upregulation of Cbfa1 and downregulation of smooth muscle lineage markers. Circ Res. 2001; 89: 1147-1154Steitz SA, Speer MY, Curinga G et al. Smooth muscle cell phenotypic transition associated with calcification: upregulation of Cbfa1 and downregulation of smooth muscle lineage markers. Circ Res. 2001; 89: 1147-1154Speer MY, Li X, Hiremath PG, Giachelli CM. Runx2 / Cbfa1. but not loss of myocardin, is required for smooth muscle cell lineage reprogramming toward osteochondrogenesis. J Cell Biochem. 2010; 110: 935-947. doi: 10.1002/jcb.22607Speer MY, Li X, Hiremath PG, Giachelli CM. Runx2 / Cbfa1. but not loss of myocardin, is required for smooth muscle cell lineage reprogramming toward osteochondrogenesis. J Cell Biochem. 2010; 110: 935-947. doi: 10.1002/jcb.22607Shioi ANY, Jono S, Koyama H et al. Glycerophosphate accelerates calcification in cultured bovine vascular smooth muscle cells. Arterioscler Throm Vasc Biol. 1995; 17: 1135-1142Shioi ANY, Jono S, Koyama H et al. Glycerophosphate accelerates calcification in cultured bovine vascular smooth muscle cells. Arterioscler Throm Vasc Biol. 1995; 17: 1135-1142Chen NX, O’Neill KD, Duan D, Moe SM. Phosphorus and uremic serum up -regulate osteopontin expression in vascular smooth muscle cells. Kidney Int. 2002; 62: 1724-1731Chen NX, O’Neill KD, Duan D, Moe SM. Phosphorus and uremic serum up -regulate osteopontin expression in vascular smooth muscle cells. Kidney Int. 2002; 62: 1724-1731Mathew S, Tustison KS, Sugatani T et al. The mechanism of phosphorus as a cardiovascular risk factor in CKD. J Am Soc Nephrol. 2008; 19: 1092-1105. doi: 10.1681/ASN.2007070760Mathew S, Tustison KS, Sugatani T et al. The mechanism of phosphorus as a cardiovascular risk factor in CKD. J Am Soc Nephrol. 2008; 19: 1092-1105. doi: 10.1681/ASN.2007070760Leopold JA. Vascular calcification: Mechanisms of vascular smooth muscle cell calcification. Trends Cardiovasc Med. 2015; 25(4): 267-274. doi: 10.1016/j.tcm.2014.10.021Leopold JA. Vascular calcification: Mechanisms of vascular smooth muscle cell calcification. Trends Cardiovasc Med. 2015; 25(4): 267-274. doi: 10.1016/j.tcm.2014.10.021Gittenberger-de Groot AC, Winter EM, Bartelings MM et al. The arterial and cardiac epicardium in development, disease and repair. Differentiation. 2012; 84(1): 41-53. doi: 10.1016/j.diff.2012.05.002Gittenberger-de Groot AC, Winter EM, Bartelings MM et al. The arterial and cardiac epicardium in development, disease and repair. Differentiation. 2012; 84(1): 41-53. doi: 10.1016/j.diff.2012.05.002Von Gise A, Pu WT. Endocardial and epicardial epithelial to mesenchymal transitions in heart development and disease. Circ Res. 2012; 110(12): 1628-1645. doi: 10.1161/CIRCRE-SAHA.111.259960Von Gise A, Pu WT. Endocardial and epicardial epithelial to mesenchymal transitions in heart development and disease. Circ Res. 2012; 110(12): 1628-1645. doi: 10.1161/CIRCRE-SAHA.111.259960Mill C, George SJ. Wnt signalling in smooth muscle cells and its role in cardiovascular disorders. Cardiovasc Res. 2012; 95(2): 233-240. doi: 10.1093/cvr/cvs141Mill C, George SJ. Wnt signalling in smooth muscle cells and its role in cardiovascular disorders. Cardiovasc Res. 2012; 95(2): 233-240. doi: 10.1093/cvr/cvs141Liu H, Fergusson MM, Castilho RM et al. Augmented Wnt signaling in a mammalian model of accelerated aging. Science. 2007; 317: 803-806Liu H, Fergusson MM, Castilho RM et al. Augmented Wnt signaling in a mammalian model of accelerated aging. Science. 2007; 317: 803-806Kawakami T, Ren S, Duffield JS. Wnt signalling in kidney diseases: dual roles in renal injury and repair. J Pathol. 2013; 229(2): 221-231. doi: 10.1002/path.4121Kawakami T, Ren S, Duffield JS. Wnt signalling in kidney diseases: dual roles in renal injury and repair. J Pathol. 2013; 229(2): 221-231. doi: 10.1002/path.4121Sage AP, Lu J, Tintut Y, Demer LL. Hyperphosphatemia-induced nanocrystals upregulate the expression of bone morphogenetic protein-2 and osteopontin genes in mouse smooth muscle cells in vitro. Kidney Int. 2011; 79: 414-422. doi: 10.1038/ ki.2010.390Sage AP, Lu J, Tintut Y, Demer LL. Hyperphosphatemia-induced nanocrystals upregulate the expression of bone morphogenetic protein-2 and osteopontin genes in mouse smooth muscle cells in vitro. Kidney Int. 2011; 79: 414-422. doi: 10.1038/ ki.2010.390Li X, Yang HY, Giachelli CM. BMP-2 promotes phosphate uptake, phenotypic modulation, and calcification of human vascular smooth muscle cells. Atherosclerosis. 2008; 199: 271-277. doi: 10.1016/j.atherosclerosis.2007.11.031Li X, Yang HY, Giachelli CM. BMP-2 promotes phosphate uptake, phenotypic modulation, and calcification of human vascular smooth muscle cells. Atherosclerosis. 2008; 199: 271-277. doi: 10.1016/j.atherosclerosis.2007.11.031Ross S, Hill CS. How the Smads regulate transcription. Int J Biochem Cell Biol. 2008; 40: 383-408Ross S, Hill CS. How the Smads regulate transcription. Int J Biochem Cell Biol. 2008; 40: 383-408Zhang YW, Yasui N, Ito K et al. A RUNX2/PEBP2alpha A/ CBFA1 mutation displaying impaired transactivation and Smad interaction in cleidocranial dysplasia. Proc Natl Acad Sci USA. 2000; 97: 10549-10554Zhang YW, Yasui N, Ito K et al. A RUNX2/PEBP2alpha A/ CBFA1 mutation displaying impaired transactivation and Smad interaction in cleidocranial dysplasia. Proc Natl Acad Sci USA. 2000; 97: 10549-10554Vattikuti R, Towler DA. Osteogenic regulation of vascular calcification: an early perspective. Am J Physiol Endocrinol Metab. 2004; 286: E686-E696Vattikuti R, Towler DA. Osteogenic regulation of vascular calcification: an early perspective. Am J Physiol Endocrinol Metab. 2004; 286: E686-E696Hruska KA, Mathew S, Saab G. Bone morphogenetic proteins in vascular calcification. Circ Res. 2005; 97: 105-114Hruska KA, Mathew S, Saab G. Bone morphogenetic proteins in vascular calcification. Circ Res. 2005; 97: 105-114Lian JB, Javed A, Zaidi SK et al. Regulatory controls for osteoblast growth and differentiation: role of Runx/Cbfa/AML factors. Crit Rev Eukaryot Gene Expr. 2004; 14: 1-41Lian JB, Javed A, Zaidi SK et al. Regulatory controls for osteoblast growth and differentiation: role of Runx/Cbfa/AML factors. Crit Rev Eukaryot Gene Expr. 2004; 14: 1-41Baron R, Rawadi G. Wnt signaling and the regulation of bone mass. Curr Osteoporos Rep. 2007; 5: 73-80Baron R, Rawadi G. Wnt signaling and the regulation of bone mass. Curr Osteoporos Rep. 2007; 5: 73-80Shao JS, Cai J, Towler DA. Molecular mechanisms of vascular calcification: lessons learned from the aorta. Arterioscler Thromb Vasc Biol. 2006; 26: 1423-1430Shao JS, Cai J, Towler DA. Molecular mechanisms of vascular calcification: lessons learned from the aorta. Arterioscler Thromb Vasc Biol. 2006; 26: 1423-1430Shao JS, Cheng SL, Pingsterhaus JM et al. Msx2 promotes cardiovascular calcification by activating paracrine Wnt signals. J Clin Invest. 2005; 115: 1210-1220Shao JS, Cheng SL, Pingsterhaus JM et al. Msx2 promotes cardiovascular calcification by activating paracrine Wnt signals. J Clin Invest. 2005; 115: 1210-1220Ермоленко ВМ. Ренальная остеодистрофия - начальные события. Клиническая нефролoгия. 2014; (2): 10-14 [Ermolenko VM. Renal’naya osteodistrofiya - nachal’nye sobytiya. Klinicheskaya nefrolgiya. 2014; (2): 10-14]Ермоленко ВМ. Ренальная остеодистрофия - начальные события. Клиническая нефролoгия. 2014; (2): 10-14 [Ermolenko VM. Renal’naya osteodistrofiya - nachal’nye sobytiya. Klinicheskaya nefrolgiya. 2014; (2): 10-14]Weishaar RE, Kim SN, Saunders DE et al. Involvement of vitamin D3 with cardiovascular function. III. Effects on physical and morphological properties. Am J Physiol. 1990; 258: E134-E142Weishaar RE, Kim SN, Saunders DE et al. Involvement of vitamin D3 with cardiovascular function. III. Effects on physical and morphological properties. Am J Physiol. 1990; 258: E134-E142Xiang W, Kong J, Chen S et al.Cardiac hypertrophy in vitamin D receptor knockout mice: role of the systemic and cardiac renin -angiotensin systems. Am J Physiol Endocrinol Metab. 2005; 288: E125-132Xiang W, Kong J, Chen S et al.Cardiac hypertrophy in vitamin D receptor knockout mice: role of the systemic and cardiac renin -angiotensin systems. Am J Physiol Endocrinol Metab. 2005; 288: E125-132Смирнов АВ, Волков МM, Добронравов ВА. Кардиопротективные эффекты D-гормона у больных с хронической болезнью почек: обзор литературы и собственные данные. Нефрология 2009; 13(1): 30-38 [Smirnov AV, Volkov MM, Dobronravov VA. Kardioprotektivnye ehffekty D-gormona u bol’nyh s hronicheskoj bolezn’yu pochek: obzor literatury i sobstvennye dannye. Nefrologiya. 2009; 13(1): 30-38]Смирнов АВ, Волков МM, Добронравов ВА. Кардиопротективные эффекты D-гормона у больных с хронической болезнью почек: обзор литературы и собственные данные. Нефрология 2009; 13(1): 30-38 [Smirnov AV, Volkov MM, Dobronravov VA. Kardioprotektivnye ehffekty D-gormona u bol’nyh s hronicheskoj bolezn’yu pochek: obzor literatury i sobstvennye dannye. Nefrologiya. 2009; 13(1): 30-38]Nigwekar SU, Thadhani R. Vitamin D receptor activation: cardiovascular and renal implications. Kidney Int Suppl (2011). 2013; 3(5): 4 27 - 430Nigwekar SU, Thadhani R. Vitamin D receptor activation: cardiovascular and renal implications. Kidney Int Suppl (2011). 2013; 3(5): 4 27 - 430Li YC. Vitamin D: roles in renal and cardiovascular protection. Curr Opin Nephrol Hypertens. 2012; 21(1): 72-79. doi: 10.1097/MNH.0b013e32834de4eeLi YC. Vitamin D: roles in renal and cardiovascular protection. Curr Opin Nephrol Hypertens. 2012; 21(1): 72-79. doi: 10.1097/MNH.0b013e32834de4eeMathew S, Lund RJ, Chaudhary LR et al. Vitamin D receptor activators can protect against vascular calcification. J Am Soc Nephrol. 2008; 19: 1509-1519. doi: 10.1681/ASN.2007080902Mathew S, Lund RJ, Chaudhary LR et al. Vitamin D receptor activators can protect against vascular calcification. J Am Soc Nephrol. 2008; 19: 1509-1519. doi: 10.1681/ASN.2007080902Mizobuchi M, Finch JL, Martin DR et al. Differential effects of vitamin D receptor activators on vascular calcification in uremic rats. Kidney Int. 2007; 72: 709-715Mizobuchi M, Finch JL, Martin DR et al. Differential effects of vitamin D receptor activators on vascular calcification in uremic rats. Kidney Int. 2007; 72: 709-715Martfnez-Moreno JM, Mufioz-Castafieda JR, Herencia C et al. In vascular smooth muscle cells paricalcitol prevents phosphate-induced Wnt/ß-catenin activation. Am J Physiol Renal Physi ol. 2012; 303(8): F1136-144. doi: 10.1152/ajprenal.00684.2011Martfnez-Moreno JM, Mufioz-Castafieda JR, Herencia C et al. In vascular smooth muscle cells paricalcitol prevents phosphate-induced Wnt/ß-catenin activation. Am J Physiol Renal Physi ol. 2012; 303(8): F1136-144. doi: 10.1152/ajprenal.00684.2011Kolek OI, Hines ER, Jones MD et al. 1alpha,25-dihy-droxyvitamin D3 upregulates FGF-23 gene expression in bone: the final link in a renal-gastrointestinal-skeletal axis that controls phosphate transport. Am J Physiol. 2005; 289: G1036-G1042Kolek OI, Hines ER, Jones MD et al. 1alpha,25-dihy-droxyvitamin D3 upregulates FGF-23 gene expression in bone: the final link in a renal-gastrointestinal-skeletal axis that controls phosphate transport. Am J Physiol. 2005; 289: G1036-G1042Barthel TK, Mathern DR, Whitfield GK et al. 1,25-dihydroxyvitamin D(3)/VDR-mediated induction of FGF-23 as well as transcriptional control of other bone anabolic and catabolic genes that orchestrate the regulation of phosphate and calcium mineral metabolism. J Steroid Biochem Mol Biol. 2007; 103: 381-388Barthel TK, Mathern DR, Whitfield GK et al. 1,25-dihydroxyvitamin D(3)/VDR-mediated induction of FGF-23 as well as transcriptional control of other bone anabolic and catabolic genes that orchestrate the regulation of phosphate and calcium mineral metabolism. J Steroid Biochem Mol Biol. 2007; 103: 381-388Lomashvili KA, Narisawa S, Millan JL, O’Neill WC. Vascular calcification is dependent on plasma levels of pyrophosphate. Kid Int. 2014; 85: 1351-1356. doi: 10.1038/ki.2013.521Lomashvili KA, Narisawa S, Millan JL, O’Neill WC. Vascular calcification is dependent on plasma levels of pyrophosphate. Kid Int. 2014; 85: 1351-1356. doi: 10.1038/ki.2013.521Hruska KA, Mathew S, Lund RJ et al. The pathogenesis of vascular calcification in the chronic kidney disease mineral bone disorder: the links between bone and the vasculature. Sem Nephrol. 2009; 29: 156-165. doi: 10.1016/j.semnephrol.2009.01.008Hruska KA, Mathew S, Lund RJ et al. The pathogenesis of vascular calcification in the chronic kidney disease mineral bone disorder: the links between bone and the vasculature. Sem Nephrol. 2009; 29: 156-165. doi: 10.1016/j.semnephrol.2009.01.008Kokot F, Pietrek J, Srokowska S et al. 25 -Hydroxyvitamin D in patients with essential hypertension. Clin Nephrol. 1981; 16: 188-192Kokot F, Pietrek J, Srokowska S et al. 25 -Hydroxyvitamin D in patients with essential hypertension. Clin Nephrol. 1981; 16: 188-192Burgaz A, Orsini N, Larsson SC et al. Blood 25 -hydroxyvi-tamin D concentration and hypertension: a meta-analysis. J Hypertens. 2011; 29: 636-645. doi: 10.1097/HJH.0b013e32834320f9Burgaz A, Orsini N, Larsson SC et al. Blood 25 -hydroxyvi-tamin D concentration and hypertension: a meta-analysis. J Hypertens. 2011; 29: 636-645. doi: 10.1097/HJH.0b013e32834320f9Pilz S, Marz W, Wellnitz B et al. Association of vitamin D deficiency with heart failure and sudden cardiac death in a large cross -sectional study of patients referred for coronary angiography. J Clin Endocrinol Metab. 2008; 93: 3927-3935. doi: 10.1210/ jc.2008-0784Pilz S, Marz W, Wellnitz B et al. Association of vitamin D deficiency with heart failure and sudden cardiac death in a large cross -sectional study of patients referred for coronary angiography. J Clin Endocrinol Metab. 2008; 93: 3927-3935. doi: 10.1210/ jc.2008-0784Wang TJ, Pencina MJ, Booth SL et al. Vitamin D deficiency and risk of cardiovascular disease. Circulation. 2008; 117: 503-511. doi: 10.1161/CIRCULATIONAHA.107.706127Wang TJ, Pencina MJ, Booth SL et al. Vitamin D deficiency and risk of cardiovascular disease. Circulation. 2008; 117: 503-511. doi: 10.1161/CIRCULATIONAHA.107.706127Pilz S, Iodice S, Zittermann A et al. Vitamin D status and mortality risk in CKD: a meta -analysis of prospective studies. Am J Kidney Dis. 2011; 58; 374-382. doi: 10.1053/j.ajkd.2011.03.020Pilz S, Iodice S, Zittermann A et al. Vitamin D status and mortality risk in CKD: a meta -analysis of prospective studies. Am J Kidney Dis. 2011; 58; 374-382. doi: 10.1053/j.ajkd.2011.03.020Drechsler C, Verduijn M, Pilz S et al. Vitamin D status and clinical outcomes in incident dialysis patients: results from the NECOSAD study. Nephrol Dial Transplant. 2011; 26: 1024-1032. doi: 10.1093/ndt/gfq606Drechsler C, Verduijn M, Pilz S et al. Vitamin D status and clinical outcomes in incident dialysis patients: results from the NECOSAD study. Nephrol Dial Transplant. 2011; 26: 1024-1032. doi: 10.1093/ndt/gfq606Xiang W, Kong J, Chen S et al.Cardiac hypertrophy in vitamin D receptor knockout mice: role of the systemic and cardiac renin -angiotensin systems. Am J Physiol Endocrinol Metab. 2005; 288: E125-132Xiang W, Kong J, Chen S et al.Cardiac hypertrophy in vitamin D receptor knockout mice: role of the systemic and cardiac renin -angiotensin systems. Am J Physiol Endocrinol Metab. 2005; 288: E125-132Abu el Maaty MA, Gad MZ. Vitamin D deficiency and cardiovascular disease: potential mechanisms and novel perspectives. J Nutr Sci Vitaminol (Tokyo). 2013; 59(6): 479-488. doi: 10.3177/jnsv.59.479Abu el Maaty MA, Gad MZ. Vitamin D deficiency and cardiovascular disease: potential mechanisms and novel perspectives. J Nutr Sci Vitaminol (Tokyo). 2013; 59(6): 479-488. doi: 10.3177/jnsv.59.479Clemens TL, Cormier S, Eichinger A et al. Parathyroid hormone -related protein and its receptors: nuclear functions and roles in the renal and cardiovascular systems, the placental trophoblasts and the pancreatic islets. Br J Pharmacol. 2001; 134: 1113-1136Clemens TL, Cormier S, Eichinger A et al. Parathyroid hormone -related protein and its receptors: nuclear functions and roles in the renal and cardiovascular systems, the placental trophoblasts and the pancreatic islets. Br J Pharmacol. 2001; 134: 1113-1136Goettsch C, Iwata H, Aikawa E. Parathyroid hormone: critical bridge between bone metabolism and cardiovascular disease. Arterioscler Thromb Vasc Biol. 2014; 34(7): 1333-1335. doi: 10.1161/ATVBAHA.114.303637Goettsch C, Iwata H, Aikawa E. Parathyroid hormone: critical bridge between bone metabolism and cardiovascular disease. Arterioscler Thromb Vasc Biol. 2014; 34(7): 1333-1335. doi: 10.1161/ATVBAHA.114.303637Macfarlane DP, Yu N, Leese GP. Subclinical and asymptomatic parathyroid disease: implications of emerging data. Lancet Diabetes Endocrinol. 2013; 1: 329-340. doi: 10.1016/ S2213-8587(13)70083-4Macfarlane DP, Yu N, Leese GP. Subclinical and asymptomatic parathyroid disease: implications of emerging data. Lancet Diabetes Endocrinol. 2013; 1: 329-340. doi: 10.1016/ S2213-8587(13)70083-4Bosworth C, Sachs MC, Duprez D et al. Parathyroid hormone and arterial dysfunction in the multi-ethnic study of atherosclerosis. Clin Endocrinol(Oxf). 2013; 79(3): 429 -436. doi: 10.1111/cen.12163Bosworth C, Sachs MC, Duprez D et al. Parathyroid hormone and arterial dysfunction in the multi-ethnic study of atherosclerosis. Clin Endocrinol(Oxf). 2013; 79(3): 429 -436. doi: 10.1111/cen.12163Hagström E, Hellman P, Larsson TE et al. Plasma parathyroid hormone and the risk of cardiovascular mortality in the community. Circulation. 2009; 119: 2765-2771. doi: 10.1161/CIRCULATIONAHA.108.808733Hagström E, Hellman P, Larsson TE et al. Plasma parathyroid hormone and the risk of cardiovascular mortality in the community. Circulation. 2009; 119: 2765-2771. doi: 10.1161/CIRCULATIONAHA.108.808733Нagström E, Michaëlsson K, Melhus H et al. Plasma-parathyroid hormone is associated with subclinical and clinical atherosclerotic disease in 2 community -based cohorts. Arterioscler Thromb Vasc Biol. 2014; 34: 1567-1573. doi: 10.1161/ATVBAHA.113.303062Нagström E, Michaëlsson K, Melhus H et al. Plasma-parathyroid hormone is associated with subclinical and clinical atherosclerotic disease in 2 community -based cohorts. Arterioscler Thromb Vasc Biol. 2014; 34: 1567-1573. doi: 10.1161/ATVBAHA.113.303062Nakayama K, Nakao K, Takatori Y et al. Long -term effect of cinacalcet hydrochloride on abdominal aortic calcification in patients on hemodialysis with secondary hyperparathyroidism. Int J Nephrol Renovasc Dis. 2013; 7: 25-33. doi: 10.2147/IJNRD.S54731Nakayama K, Nakao K, Takatori Y et al. Long -term effect of cinacalcet hydrochloride on abdominal aortic calcification in patients on hemodialysis with secondary hyperparathyroidism. Int J Nephrol Renovasc Dis. 2013; 7: 25-33. doi: 10.2147/IJNRD.S54731Lee M, Partridge NC. Parathyroid hormone signaling in bone and kidney. Curr Opin Nephrol Hypertens. 2009; 18(4): 298-302. doi: 10.1097/MNH.0b013e32832c2264Lee M, Partridge NC. Parathyroid hormone signaling in bone and kidney. Curr Opin Nephrol Hypertens. 2009; 18(4): 298-302. doi: 10.1097/MNH.0b013e32832c2264Keller H, Kneissel M. SOST is a target gene for PTH in bone. Bone. 2005; 37(2): 148-158Keller H, Kneissel M. SOST is a target gene for PTH in bone. Bone. 2005; 37(2): 148-158Cheng SL, Shao JS, Halstead LR et al. Activation of vascular smooth muscle parathyroid hormone receptor inhibits Wnt/beta-catenin signaling and aortic fibrosis in diabetic arteriosclerosis. Circ Res. 2010; 107: 271-282. doi: 10.1161/CIRCRESAHA.110.219899Cheng SL, Shao JS, Halstead LR et al. Activation of vascular smooth muscle parathyroid hormone receptor inhibits Wnt/beta-catenin signaling and aortic fibrosis in diabetic arteriosclerosis. Circ Res. 2010; 107: 271-282. doi: 10.1161/CIRCRESAHA.110.219899Sebastian EM, Suva LJ, Friedman PA. Differential effects of intermittent PTH(1-34) and PTH(7-34) on bone microarchitecture and aortic calcification in experimental renal failure. Bone. 2008; 43: 1022-30. doi: 10.1016/j.bone.2008.07.250Sebastian EM, Suva LJ, Friedman PA. Differential effects of intermittent PTH(1-34) and PTH(7-34) on bone microarchitecture and aortic calcification in experimental renal failure. Bone. 2008; 43: 1022-30. doi: 10.1016/j.bone.2008.07.250Shao JS, Cheng SL, Charlton-Kachigian N et al. Teripa-ratide (human parathyroid hormone (1-34)) inhibits osteogenic vascular calcification in diabetic low density lipoprotein receptor-deficient mice. J Biol Chem. 2003; 278: 50195-50202Shao JS, Cheng SL, Charlton-Kachigian N et al. Teripa-ratide (human parathyroid hormone (1-34)) inhibits osteogenic vascular calcification in diabetic low density lipoprotein receptor-deficient mice. J Biol Chem. 2003; 278: 50195-50202Suttamanatwong S, Franceschi RT, Carlson AE, Go-palakrishnan R. Regulation of matrix Gla protein by parathyroid hormone in MC3T3-E1 osteoblast-like cells involves protein kinase A and extracellular signal-regulated kinase pathways. J Cell Biochem. 2007; 102: 496-505.Suttamanatwong S, Franceschi RT, Carlson AE, Go-palakrishnan R. Regulation of matrix Gla protein by parathyroid hormone in MC3T3-E1 osteoblast-like cells involves protein kinase A and extracellular signal-regulated kinase pathways. J Cell Biochem. 2007; 102: 496-505.Gopalakrishnan R, Suttamanatwong S, Carlson AE, Franceschi RT. Role of matrix Gla protein in parathyroid hormone inhibition of osteoblast mineralization. Cells Tissues Organs. 2005; 181: 166-175Gopalakrishnan R, Suttamanatwong S, Carlson AE, Franceschi RT. Role of matrix Gla protein in parathyroid hormone inhibition of osteoblast mineralization. Cells Tissues Organs. 2005; 181: 166-175Yao Y et al. Inhibition of bone morphogenetic proteins protects against atherosclerosis and vascular calcification. Circ Res. 2010; 107: 485-494. doi: 10.1161/CIRCRESAHA.110.219071Yao Y et al. Inhibition of bone morphogenetic proteins protects against atherosclerosis and vascular calcification. Circ Res. 2010; 107: 485-494. doi: 10.1161/CIRCRESAHA.110.219071Gutierrez OM, Wolf M, Taylor EN. Fibroblast growth factor 23, cardiovascular disease risk factors, and phosphorus intake in the Health Professionals Follow -up Study. Clin J Am Soc Nephrol. 2011; 6: 2871-2878. doi: 10.2215/CJN.02740311Gutierrez OM, Wolf M, Taylor EN. Fibroblast growth factor 23, cardiovascular disease risk factors, and phosphorus intake in the Health Professionals Follow -up Study. Clin J Am Soc Nephrol. 2011; 6: 2871-2878. doi: 10.2215/CJN.02740311Manghat P, Fraser WD, Wierzbicki AS et al. Fibroblast growth factor -23 is associated with C -reactive protein, serum phosphate and bone mineral density in chronic kidney disease. Osteoporos Int. 2010; 21: 1853-1861. doi: 10.1007/s00198-009-1142-4Manghat P, Fraser WD, Wierzbicki AS et al. Fibroblast growth factor -23 is associated with C -reactive protein, serum phosphate and bone mineral density in chronic kidney disease. Osteoporos Int. 2010; 21: 1853-1861. doi: 10.1007/s00198-009-1142-4Isakova T, Xie H, Yang W et al. Chronic Renal Insufficiency Cohort (CRIC) Study Group : Fibroblast growth factor 23 and risks of mortality and end -stage renal disease in patients with chronic kidney disease. JAMA. 2011; 305: 2432-2439. doi: 10.1001/jama.2011.826Isakova T, Xie H, Yang W et al. Chronic Renal Insufficiency Cohort (CRIC) Study Group : Fibroblast growth factor 23 and risks of mortality and end -stage renal disease in patients with chronic kidney disease. JAMA. 2011; 305: 2432-2439. doi: 10.1001/jama.2011.826Fliser D, Kollerits B, Neyer U et al. Fibroblast growth factor 23 (FGF23) predicts progression of chronic kidney disease: The Mild to Moderate Kidney Disease (MMKD) Study. J Am Soc Nephrol. 2007; 18: 2600-2608Fliser D, Kollerits B, Neyer U et al. Fibroblast growth factor 23 (FGF23) predicts progression of chronic kidney disease: The Mild to Moderate Kidney Disease (MMKD) Study. J Am Soc Nephrol. 2007; 18: 2600-2608Wolf M, Molnar MZ, Amaral AP et al. Elevated fibroblast growth factor 23 is a risk factor for kidney transplant loss and mortality. J Am Soc Nephrol. 2011; 22: 956-966. doi: 10.1681/ ASN.2010080894Wolf M, Molnar MZ, Amaral AP et al. Elevated fibroblast growth factor 23 is a risk factor for kidney transplant loss and mortality. J Am Soc Nephrol. 2011; 22: 956-966. doi: 10.1681/ ASN.2010080894Gutiérrez OM, Mannstadt M, Isakova T et al. Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med. 2008; 359: 584-592. doi: 10.1056/ NEJMoa0706130Gutiérrez OM, Mannstadt M, Isakova T et al. Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med. 2008; 359: 584-592. doi: 10.1056/ NEJMoa0706130Lundberg S, Qureshi AR, Olivecrona S et al. FGF23, albuminuria, and disease progression in patients with chronic IgA nephropathy. Clin J Am Soc Nephrol. 2012; 7: 727-734. doi: 10.2215/CJN.10331011Lundberg S, Qureshi AR, Olivecrona S et al. FGF23, albuminuria, and disease progression in patients with chronic IgA nephropathy. Clin J Am Soc Nephrol. 2012; 7: 727-734. doi: 10.2215/CJN.10331011Ix JH, Katz R, Kestenbaum BR et al. Fibroblast growth factor - 23 and death, heart failure, and cardiovascular events in community - living individuals: CHS (Cardiovascular Health Study). J Am Coll Cardiol. 2012; 60: 200-207. doi: 10.1016/j.jacc.2012.03.040Ix JH, Katz R, Kestenbaum BR et al. Fibroblast growth factor - 23 and death, heart failure, and cardiovascular events in community - living individuals: CHS (Cardiovascular Health Study). J Am Coll Cardiol. 2012; 60: 200-207. doi: 10.1016/j.jacc.2012.03.040Ärnlöv J, Carlsson AC, Sundström J et al. Higher fibroblast growth factor - 23 increases the risk of all - cause and cardiovascular mortality in the community. Kidney Int. 2013; 83: 160-166. doi: 10.1038/ki.2012.327Ärnlöv J, Carlsson AC, Sundström J et al. Higher fibroblast growth factor - 23 increases the risk of all - cause and cardiovascular mortality in the community. Kidney Int. 2013; 83: 160-166. doi: 10.1038/ki.2012.327Ärnlöv J, Carlsson AC, Sundström J et al. Serum FGF23 and Risk of Cardiovascular Events in Relation to Mineral Metabolism and Cardiovascular Pathology. Clin J Am Soc Nephrol. 2013; 8(5): 781-786. doi: 10.2215/CJN.09570912Ärnlöv J, Carlsson AC, Sundström J et al. Serum FGF23 and Risk of Cardiovascular Events in Relation to Mineral Metabolism and Cardiovascular Pathology. Clin J Am Soc Nephrol. 2013; 8(5): 781-786. doi: 10.2215/CJN.09570912Jovanovich A, Ix JH, Gottdiener J et al. Fibroblast growth factor 23, left ventricular mass, and left ventricular hypertrophy in community - dwelling older adults. Atherosclerosis. 2013; 231(1): 114-119. doi: 10.1016/j.atherosclerosis.2013.09.002Jovanovich A, Ix JH, Gottdiener J et al. Fibroblast growth factor 23, left ventricular mass, and left ventricular hypertrophy in community - dwelling older adults. Atherosclerosis. 2013; 231(1): 114-119. doi: 10.1016/j.atherosclerosis.2013.09.002Scialla JJ, Xie H, Rahman M et al.Chronic Renal Insufficiency Cohort (CRIC) Study Investigators. Fibroblast growth factor -23 and cardiovascular events in CKD. J Am Soc Nephrol. 2014; 25(2): 349-360. doi: 10.1681/ASN.2013050465Scialla JJ, Xie H, Rahman M et al.Chronic Renal Insufficiency Cohort (CRIC) Study Investigators. Fibroblast growth factor -23 and cardiovascular events in CKD. J Am Soc Nephrol. 2014; 25(2): 349-360. doi: 10.1681/ASN.2013050465Faul C, Amaral AP, Oskouei B et al. FGF23 induces left ventricular hypertrophy. J Clin Invest. 2011; 121(11): 4393-4408. doi: 10.1172/JCI46122Faul C, Amaral AP, Oskouei B et al. FGF23 induces left ventricular hypertrophy. J Clin Invest. 2011; 121(11): 4393-4408. doi: 10.1172/JCI46122Shibata K, Fujita S, Morita H et al.Association between circulating fibroblast growth factor 23, a-Klotho, and the left ventricular ejection fraction and left ventricular mass in cardiology inpatients. PLoS One. 2013; 8(9): e73184. doi: 10.1371/journal. pone.0073184Shibata K, Fujita S, Morita H et al.Association between circulating fibroblast growth factor 23, a-Klotho, and the left ventricular ejection fraction and left ventricular mass in cardiology inpatients. PLoS One. 2013; 8(9): e73184. doi: 10.1371/journal. pone.0073184Seifert ME, De Las Fuentes L, Ginsberg C et al. Left ventricular mass progression despite stable blood pressure and kidney function in stage 3 chronic kidney disease. Am J Nephrol. 2014; 39(5): 392 - 399. doi: 10.1159/000362251Seifert ME, De Las Fuentes L, Ginsberg C et al. Left ventricular mass progression despite stable blood pressure and kidney function in stage 3 chronic kidney disease. Am J Nephrol. 2014; 39(5): 392 - 399. doi: 10.1159/000362251Seiler S, Rogacev KS, Roth HJ et al. Associations of FGF-23 and sKlotho with cardiovascular outcomes among patients with CKD stages 2-4. Clin J Am Soc Nephrol. 2014; 9(6): 1049 -1058. doi: 10.2215/CJN.07870713Seiler S, Rogacev KS, Roth HJ et al. Associations of FGF-23 and sKlotho with cardiovascular outcomes among patients with CKD stages 2-4. Clin J Am Soc Nephrol. 2014; 9(6): 1049 -1058. doi: 10.2215/CJN.07870713Molkentin JD, Lu J, Antos C et al. A calcineurin -dependent transcriptional pathway for cardiac hypertrophy. Cell. 1998; 93(2): 215-228Molkentin JD, Lu J, Antos C et al. A calcineurin -dependent transcriptional pathway for cardiac hypertrophy. Cell. 1998; 93(2): 215-228Komuro I, YazakiY Control of cardiac gene expression by mechanical stress. Annu Rev Physiol. 1993; 55: 55-75Komuro I, YazakiY Control of cardiac gene expression by mechanical stress. Annu Rev Physiol. 1993; 55: 55-75Itoh N, Ohta H. Pathophysiological roles of FGF signaling in the heart. Front Physiol. 2013; 4: 247. doi: 10.3389/fphys.2013.0024Itoh N, Ohta H. Pathophysiological roles of FGF signaling in the heart. Front Physiol. 2013; 4: 247. doi: 10.3389/fphys.2013.0024Kendrick J, Cheung AK, Kaufman JS et al. FGF - 23 associates with death, cardiovascular events, and initiation of chronic dialysis. J Am Soc Nephrol. 2011; 22: 1913-1922. doi: 10.1681/ASN.2010121224Kendrick J, Cheung AK, Kaufman JS et al. FGF - 23 associates with death, cardiovascular events, and initiation of chronic dialysis. J Am Soc Nephrol. 2011; 22: 1913-1922. doi: 10.1681/ASN.2010121224Seiler S, Reichart B, Roth D et al. FGF -23 and future cardiovascular events in patients with chronic kidney disease before initiation of dialysis treatment. Nephrol Dial Transplant. 2010; 25: 3983-3989. doi: 10.1093/ndt/gfq309Seiler S, Reichart B, Roth D et al. FGF -23 and future cardiovascular events in patients with chronic kidney disease before initiation of dialysis treatment. Nephrol Dial Transplant. 2010; 25: 3983-3989. doi: 10.1093/ndt/gfq309Mirza MA, Larsson A, Lind L et al. Circulating fibroblast growth factor - 23 is associated with vascular dysfunction in the community. Atherosclerosis. 2009; 205: 385-390. doi: 10.1016/j. atherosclerosis.2009.01.001Mirza MA, Larsson A, Lind L et al. Circulating fibroblast growth factor - 23 is associated with vascular dysfunction in the community. Atherosclerosis. 2009; 205: 385-390. doi: 10.1016/j. atherosclerosis.2009.01.001Parker BD, Schurgers LJ, Brandenburg VM et al. The associations of fibroblast growth factor 23 and uncarboxylated matrix Gla protein with mortality in coronary artery disease: the Heart and Soul Study. Ann Intern Med. 2010; 152: 640-648. doi: 10.7326/0003-4819-152-10-201005180-00004Parker BD, Schurgers LJ, Brandenburg VM et al. The associations of fibroblast growth factor 23 and uncarboxylated matrix Gla protein with mortality in coronary artery disease: the Heart and Soul Study. Ann Intern Med. 2010; 152: 640-648. doi: 10.7326/0003-4819-152-10-201005180-00004Taylor EN, Rimm EB, Stampfer MJ et al. Plasma fibroblast growth factor 23, parathyroid hormone, phosphorus, and risk of coronary heart disease. Am Heart J. 2011; 161: 956-962. doi: 10.1016/j.ahj.2011.02.012Taylor EN, Rimm EB, Stampfer MJ et al. Plasma fibroblast growth factor 23, parathyroid hormone, phosphorus, and risk of coronary heart disease. Am Heart J. 2011; 161: 956-962. doi: 10.1016/j.ahj.2011.02.012Srivaths PR, Goldstein SL, Silverstein DM et al. Elevated FGF 23 and phosphorus are associated with coronary calcification in hemodialysis patients. Pediatr Nephrol. 2011; 26: 945-951. doi: 10.1007/s00467-011-1822-0Srivaths PR, Goldstein SL, Silverstein DM et al. Elevated FGF 23 and phosphorus are associated with coronary calcification in hemodialysis patients. Pediatr Nephrol. 2011; 26: 945-951. doi: 10.1007/s00467-011-1822-0Roos M, Lutz J, Salmhofer H et al. Relation between plasma fibroblast growth factor-23, serum fetuin-A levels and coronary artery calcification evaluated by multislice computed tomography in patients with normal kidney function. Clin Endocrinol (Oxf). 2008; 68: 660-665. doi: 10.1111/j.1365-2265.2007.03074.xRoos M, Lutz J, Salmhofer H et al. Relation between plasma fibroblast growth factor-23, serum fetuin-A levels and coronary artery calcification evaluated by multislice computed tomography in patients with normal kidney function. Clin Endocrinol (Oxf). 2008; 68: 660-665. doi: 10.1111/j.1365-2265.2007.03074.xKuro -o M, Matsumura Y, Aizawa H et al. Mutation of the mouse Klotho gene leads to a syndrome resembling ageing. Nature. 1997; 390: 45-51Kuro -o M, Matsumura Y, Aizawa H et al. Mutation of the mouse Klotho gene leads to a syndrome resembling ageing. Nature. 1997; 390: 45-51Kuro - o М. Phosphate and Klotho. Kidney Intl. 2011; 79(121): S20-S23. doi: 10.1038/ki.2011.26Kuro - o М. Phosphate and Klotho. Kidney Intl. 2011; 79(121): S20-S23. doi: 10.1038/ki.2011.26Dai B, David V, Martin A et al. A comparative transcrip-tome analysis identifying FGF23 regulated genes in the kidney of a mouse CKD model. PLoS One. 2012; 7: e44161. doi: 10.1371/journal.pone.0044161Dai B, David V, Martin A et al. A comparative transcrip-tome analysis identifying FGF23 regulated genes in the kidney of a mouse CKD model. PLoS One. 2012; 7: e44161. doi: 10.1371/journal.pone.0044161Hu MC, Kuro -o M, Moe OW. Secreted klotho and chronic kidney disease. Adv Exp Med Biol. 2012; 728: 126-157. doi: 10.1007/978-1-4614-0887-1_9Hu MC, Kuro -o M, Moe OW. Secreted klotho and chronic kidney disease. Adv Exp Med Biol. 2012; 728: 126-157. doi: 10.1007/978-1-4614-0887-1_9Lim K, Lu TS, Molostvov G et al. Vascular Klotho deficiency potentiates the development of human artery calcification and mediates resistance to fibroblast growth factor 23. Circulation. 2012; 125: 2243-2255. doi: 10.1007/978-1-4614-0887-1_9Lim K, Lu TS, Molostvov G et al. Vascular Klotho deficiency potentiates the development of human artery calcification and mediates resistance to fibroblast growth factor 23. Circulation. 2012; 125: 2243-2255. doi: 10.1007/978-1-4614-0887-1_9Van Venrooij NA, Pereira RC, Tintut Y et al. FGF23 protein expression in coronary arteries is associated with impaired kidney function. Nephrol Dial Transplant. 2014; 29(8): 1525 -1532. doi: 10.1093/ndt/gft523Van Venrooij NA, Pereira RC, Tintut Y et al. FGF23 protein expression in coronary arteries is associated with impaired kidney function. Nephrol Dial Transplant. 2014; 29(8): 1525 -1532. doi: 10.1093/ndt/gft523Mencke R, Harms G, Mirkovic K et al. Membrane-bound Klotho is not expressed endogenously in healthy or uraemic human vascular tissue. Cardiovasc Res. 2015; 108(2): 220-231. doi: 10.1093/cvr/cvv187Mencke R, Harms G, Mirkovic K et al. Membrane-bound Klotho is not expressed endogenously in healthy or uraemic human vascular tissue. Cardiovasc Res. 2015; 108(2): 220-231. doi: 10.1093/cvr/cvv187Hu MC, Shi M, Zhang J et al. Klotho deficiency causes vascular calcification in chronic kidney disease. J Am Soc Nephrol. 2011; 22: 124-136. doi: 10.1681/ASN.2009121311Hu MC, Shi M, Zhang J et al. Klotho deficiency causes vascular calcification in chronic kidney disease. J Am Soc Nephrol. 2011; 22: 124-136. doi: 10.1681/ASN.2009121311Zhao Y, Banerjee S, Dey N et al. Klotho depletion contributes to increased inflammation in kidney of the db/db mouse model of diabetes via RelA (serine)536 phosphorylation. Diabetes. 2011; 60; 1907-1916. doi: 10.2337/db10-1262Zhao Y, Banerjee S, Dey N et al. Klotho depletion contributes to increased inflammation in kidney of the db/db mouse model of diabetes via RelA (serine)536 phosphorylation. Diabetes. 2011; 60; 1907-1916. doi: 10.2337/db10-1262Xu Y1, Sun Z. Molecular basis of Klotho: from gene to function in aging. Endocr Rev. 2015; 36(2): 174-193. doi: 10.1210/er.2013-1079Xu Y1, Sun Z. Molecular basis of Klotho: from gene to function in aging. Endocr Rev. 2015; 36(2): 174-193. doi: 10.1210/er.2013-1079Hu MC, Shi M, Zhang J et al. Klotho deficiency causes vascular calcification in chronic kidney disease. J Am Soc Nephrol. 2011; 22: 124-136. doi: 10.1681/ASN.2009121311Hu MC, Shi M, Zhang J et al. Klotho deficiency causes vascular calcification in chronic kidney disease. J Am Soc Nephrol. 2011; 22: 124-136. doi: 10.1681/ASN.2009121311Dermaku-Sopjani M, Sopjani M, Saxena A et al. Downregulation of NaPi-IIa and NaPi-IIb Na-coupled phosphate transporters by coexpression of Klotho. Cell Physiol Biochem. 2011; 28: 251-258. doi: 10.1159/000331737Dermaku-Sopjani M, Sopjani M, Saxena A et al. Downregulation of NaPi-IIa and NaPi-IIb Na-coupled phosphate transporters by coexpression of Klotho. Cell Physiol Biochem. 2011; 28: 251-258. doi: 10.1159/000331737De Oliveira RM. Klotho RNAi induces premature senescence of human cells via a p53/p21 dependent pathway. FEBS Lett. 2006; 580: 5753-5758De Oliveira RM. Klotho RNAi induces premature senescence of human cells via a p53/p21 dependent pathway. FEBS Lett. 2006; 580: 5753-5758Nakano-Kurimoto R, Ikeda K et al. Replicative senescence of vascular smooth muscle cells enhances the calcification through initiating the osteoblastic transition. Am J Physiol. Heart Circ Physiol. 2009; 297: 1673-1684. doi: 10.1152/ajpheart.00455.2009Nakano-Kurimoto R, Ikeda K et al. Replicative senescence of vascular smooth muscle cells enhances the calcification through initiating the osteoblastic transition. Am J Physiol. Heart Circ Physiol. 2009; 297: 1673-1684. doi: 10.1152/ajpheart.00455.2009Kuro -o M. Klotho as a regulator of oxidative stress and senescence. Biol Chem. 2008; 389(3): 233-241. doi: 10.1515/BC.2008.028Kuro -o M. Klotho as a regulator of oxidative stress and senescence. Biol Chem. 2008; 389(3): 233-241. doi: 10.1515/BC.2008.028Kusaba T, Okigawa M, Matui A et al. Klotho is associated with VEGF receptor -2 and the transient receptor potential canonical -1 Ca2+ channel to maintain endothelial integrity. Proc Natl Acad Sci USA. 2010; 107(45): 19308-19313. doi: 10.1073/pnas.1008544107Kusaba T, Okigawa M, Matui A et al. Klotho is associated with VEGF receptor -2 and the transient receptor potential canonical -1 Ca2+ channel to maintain endothelial integrity. Proc Natl Acad Sci USA. 2010; 107(45): 19308-19313. doi: 10.1073/pnas.1008544107Nagai R, Saito Y, Ohyama Y et al. Endothelial dysfunction in the klotho mouse and downregulation of klotho gene expression in various animal models of vascular and metabolic diseases. Cell Mol Life Sci. 2000; 57(5): 738-746Nagai R, Saito Y, Ohyama Y et al. Endothelial dysfunction in the klotho mouse and downregulation of klotho gene expression in various animal models of vascular and metabolic diseases. Cell Mol Life Sci. 2000; 57(5): 738-746Kurosu H, Yamamoto M, Clark JD et al. Suppression of aging in mice by the hormone Klotho. Science. 2005; 309: 1829-1833Kurosu H, Yamamoto M, Clark JD et al. Suppression of aging in mice by the hormone Klotho. Science. 2005; 309: 1829-1833Doi S, Zou Y, Togao O et al. Klotho inhibits transforming growth factor -beta1 (TGF-beta1) signaling and suppresses renal fibrosis and cancer metastasis in mice. J Biol Chem. 2011; 286(10): 8655-8665. doi: 10.1074/jbc.M110.174037Doi S, Zou Y, Togao O et al. Klotho inhibits transforming growth factor -beta1 (TGF-beta1) signaling and suppresses renal fibrosis and cancer metastasis in mice. J Biol Chem. 2011; 286(10): 8655-8665. doi: 10.1074/jbc.M110.174037Takeshita K, Fujimori T, Kurotaki Y et al. Sinoatrial node dysfunction and early unexpected death of mice with a defect of klotho gene expression. Circulation. 2004; 109(14): 1776-1782Takeshita K, Fujimori T, Kurotaki Y et al. Sinoatrial node dysfunction and early unexpected death of mice with a defect of klotho gene expression. Circulation. 2004; 109(14): 1776-1782Nowak A, Friedrich B, Artunc F et al. Prognostic value and link to atrial fibrillation of soluble Klotho and FGF23 in hemodialysis patients. PLoS One. 2014; 9(7): e100688. doi: 10.1371/journal.pone.0100688Nowak A, Friedrich B, Artunc F et al. Prognostic value and link to atrial fibrillation of soluble Klotho and FGF23 in hemodialysis patients. PLoS One. 2014; 9(7): e100688. doi: 10.1371/journal.pone.0100688Six I, Okazaki H, Gross P et al. Direct, acute effects of Klotho and FGF23 on vascular smooth muscle and endothelium. PLoS One. 2014; 9(4): e93423. doi: 10.1371/journal.pone.0093423Six I, Okazaki H, Gross P et al. Direct, acute effects of Klotho and FGF23 on vascular smooth muscle and endothelium. PLoS One. 2014; 9(4): e93423. doi: 10.1371/journal.pone.0093423Богданова ЕО, Береснева ОН, Семенова НЮ и др. Почечная экспрессия белка αklotho ассоциирована с гипертрофией миокарда (экспериментальное исследование). Артериальная гипертензия. 2014; 20(6): 522-530 [Bogdanova EO, Beresneva ON, Semenova NYU i dr. Pochechnaya ehkspressiya belka aklotho associirovana s gipertrofiej miokarda (ehksperimental’noe issledovanie). Arterial'naya gipertenziya. 2014; 20(6): 522-530]Богданова ЕО, Береснева ОН, Семенова НЮ и др. Почечная экспрессия белка αklotho ассоциирована с гипертрофией миокарда (экспериментальное исследование). Артериальная гипертензия. 2014; 20(6): 522-530 [Bogdanova EO, Beresneva ON, Semenova NYU i dr. Pochechnaya ehkspressiya belka aklotho associirovana s gipertrofiej miokarda (ehksperimental’noe issledovanie). Arterial'naya gipertenziya. 2014; 20(6): 522-530]Xie J, Cha SK, An SW et al. Cardioprotection by Klotho through downregulation of TRPC6 channels in the mouse heart. Nat Commun. 2012; 3: 1238. doi: 10.1038/ncomms2240Xie J, Cha SK, An SW et al. Cardioprotection by Klotho through downregulation of TRPC6 channels in the mouse heart. Nat Commun. 2012; 3: 1238. doi: 10.1038/ncomms2240Hu MC, Shi M, Cho HJ. et al. Klotho and Phosphate Are Modulators of Pathologic Uremic Cardiac Remodeling. J Am Soc Nephrol. 2014. [Epub ahead of print] doi: 10.1681/ASN.2014050465Hu MC, Shi M, Cho HJ. et al. Klotho and Phosphate Are Modulators of Pathologic Uremic Cardiac Remodeling. J Am Soc Nephrol. 2014. [Epub ahead of print] doi: 10.1681/ASN.2014050465Song S, Gao P, Xiao H et al. Klotho suppresses cardiomyocyte apoptosis in mice with stress -induced cardiac injury via downregulation of endoplasmic reticulum stress. PLoS One. 2013; 8(12): e82968. doi: 10.1371/journal.pone.0082968Song S, Gao P, Xiao H et al. Klotho suppresses cardiomyocyte apoptosis in mice with stress -induced cardiac injury via downregulation of endoplasmic reticulum stress. PLoS One. 2013; 8(12): e82968. doi: 10.1371/journal.pone.0082968Maekawa Y, Ohishi M, Ikushima M et al. Klotho protein diminishes endothelial apoptosis and senescence via a mitogen -activated kinase pathway. Geriatr Gerontol Int. 2011; 11: 510-516. doi: 10.1111/j.1447-0594.2011.00699.xMaekawa Y, Ohishi M, Ikushima M et al. Klotho protein diminishes endothelial apoptosis and senescence via a mitogen -activated kinase pathway. Geriatr Gerontol Int. 2011; 11: 510-516. doi: 10.1111/j.1447-0594.2011.00699.xDe Oliveira RM. Klotho RNAi induces premature senescence of human cells via a p53/p21 dependent pathway. FEBS Lett. 2006; 580: 5753-5758De Oliveira RM. Klotho RNAi induces premature senescence of human cells via a p53/p21 dependent pathway. FEBS Lett. 2006; 580: 5753-5758Liu F, Wu S, Ren H, Gu J. Klotho suppresses RIG-I-mediated senescence-associated inflammation. Nat Cell Biol. 2011; 13: 254-262. doi: 10.1038/ncb2167Liu F, Wu S, Ren H, Gu J. Klotho suppresses RIG-I-mediated senescence-associated inflammation. Nat Cell Biol. 2011; 13: 254-262. doi: 10.1038/ncb2167Moe SM, Radcliff JS, White KE et al. The pathophysiology of early stage chronic kidney disease-mineral bone disorder (CKD-MBD) and response to phosphate binders. J Bone Miner Res. 2011; 26: 2672- 2681. doi: 10.1002/jbmr.485.Moe SM, Radcliff JS, White KE et al. The pathophysiology of early stage chronic kidney disease-mineral bone disorder (CKD-MBD) and response to phosphate binders. J Bone Miner Res. 2011; 26: 2672- 2681. doi: 10.1002/jbmr.485.Moe SM. Klotho: a master regulator of cardiovascular disease? Circulation. 2012; 125(18): 2181-2183. doi: 10.1161/CIRCULATIONAHA.112.104828Moe SM. Klotho: a master regulator of cardiovascular disease? Circulation. 2012; 125(18): 2181-2183. doi: 10.1161/CIRCULATIONAHA.112.104828Lim K, Lu TS, Molostvov G et al. Vascular Klotho deficiency potentiates the development of human artery calcification and mediates resistance to fibroblast growth factor 23. Circulation. 2012; 125(18): 2243-2255. doi: 10.1161/CIRCULATIO-NAHA.111.053405Lim K, Lu TS, Molostvov G et al. Vascular Klotho deficiency potentiates the development of human artery calcification and mediates resistance to fibroblast growth factor 23. Circulation. 2012; 125(18): 2243-2255. doi: 10.1161/CIRCULATIO-NAHA.111.053405Gorriz JL, Molina P, Cerveron MJ et al. Vascular calcification in patients with nondialysis CKD over 3 years. Clin J Am Soc Nephrol. 2015; 10(4): 654-666. doi: 10.2215/CJN.07450714Gorriz JL, Molina P, Cerveron MJ et al. Vascular calcification in patients with nondialysis CKD over 3 years. Clin J Am Soc Nephrol. 2015; 10(4): 654-666. doi: 10.2215/CJN.07450714Semba RD, Cappola AR, Sun K et al. Plasma klotho and mortality risk in older community-dwelling adults. J Gerontol A Biol Sci Med Sci. 2011; 66(7): 794-800. doi: 10.1093/gerona/glr058Semba RD, Cappola AR, Sun K et al. Plasma klotho and mortality risk in older community-dwelling adults. J Gerontol A Biol Sci Med Sci. 2011; 66(7): 794-800. doi: 10.1093/gerona/glr058Sabbagh Y, Graciolli FG, O’Brien S et al. Repression of osteocyte Wnt/ß -catenin signaling is an early event in the progression of renal osteodystrophy. J Bone Miner Res. 2012; 27: 1757-1772. doi: 10.1002/jbmr.1630Sabbagh Y, Graciolli FG, O’Brien S et al. Repression of osteocyte Wnt/ß -catenin signaling is an early event in the progression of renal osteodystrophy. J Bone Miner Res. 2012; 27: 1757-1772. doi: 10.1002/jbmr.1630Fang Y, Ginsberg C, Sugatani T et al. Early chronic kidney disease - mineral bone disorder stimulates vascular calcification. Kidney Int. 2014; 85(1): 142 -150. doi: 10.1038/ki.2013.271Fang Y, Ginsberg C, Sugatani T et al. Early chronic kidney disease - mineral bone disorder stimulates vascular calcification. Kidney Int. 2014; 85(1): 142 -150. doi: 10.1038/ki.2013.271De Oliveira RB, Graciolli FG, dos Reis LM et al. Disturbances of Wnt/ß-catenin pathway and energy metabolism in early CKD: effect of phosphate binders. Nephrol Dial Transplant. 2013; 28(10): 2510-2517. doi: 10.1093/ndt/gft234De Oliveira RB, Graciolli FG, dos Reis LM et al. Disturbances of Wnt/ß-catenin pathway and energy metabolism in early CKD: effect of phosphate binders. Nephrol Dial Transplant. 2013; 28(10): 2510-2517. doi: 10.1093/ndt/gft234Ueland T, Otterdal K, Lekva T et al. Dickkopf-1 enhances inflammatory interaction between platelets and endothelial cells and shows increased expression in atherosclerosis. Arterioscler Thromb Vasc Biol. 2009; 29(8): 1228-1234. doi: 10.1161/AT-VBAHA.109.189761Ueland T, Otterdal K, Lekva T et al. Dickkopf-1 enhances inflammatory interaction between platelets and endothelial cells and shows increased expression in atherosclerosis. Arterioscler Thromb Vasc Biol. 2009; 29(8): 1228-1234. doi: 10.1161/AT-VBAHA.109.189761Chen W, Melamed ML. Vascular calcification in predialysis CKD: common and deadly. Clin J Am Soc Nephrol. 2015; 10(4): 551-553. doi: 10.2215/CJN.01940215Chen W, Melamed ML. Vascular calcification in predialysis CKD: common and deadly. Clin J Am Soc Nephrol. 2015; 10(4): 551-553. doi: 10.2215/CJN.01940215Cheng SL, Shao JS, Behrmann A et al. Dkk1 and MSX2-Wnt7b signaling reciprocally regulate the endothelial-mesenchymal transition in aortic endothelial cells. Arterioscler Thromb Vasc Biol. 2013; 33: 1679-1689. doi: 10.1161/ATVBAHA.113.300647Cheng SL, Shao JS, Behrmann A et al. Dkk1 and MSX2-Wnt7b signaling reciprocally regulate the endothelial-mesenchymal transition in aortic endothelial cells. Arterioscler Thromb Vasc Biol. 2013; 33: 1679-1689. doi: 10.1161/ATVBAHA.113.300647Buendia P, Montes de Oca A, Madueno JA et al. Endothelial microparticles mediate inflammation-induced vascular calcification. FASEB J. 2015; 29(1): 173-181. doi: 10.1096/fj.14-249706Buendia P, Montes de Oca A, Madueno JA et al. Endothelial microparticles mediate inflammation-induced vascular calcification. FASEB J. 2015; 29(1): 173-181. doi: 10.1096/fj.14-249706Li M, Liu X, Zhang Y et al. Upregulation of Dickkopf1 by oscillatory shear stress accelerates atherogenesis. J Mol Med (Berl). 2016; 94(4): 431-441. doi: 10.1007/s00109-015-1369-9Li M, Liu X, Zhang Y et al. Upregulation of Dickkopf1 by oscillatory shear stress accelerates atherogenesis. J Mol Med (Berl). 2016; 94(4): 431-441. doi: 10.1007/s00109-015-1369-9Morena M, Jaussent I, Dupuy AM et al.Osteoprotegerin and sclerostin in chronic kidney disease prior to dialysis: potential partners in vascular calcifications. Nephrol Dial Transplant. 2015; 30(8): 1345-1356. doi: 10.1093/ndt/gfv081Morena M, Jaussent I, Dupuy AM et al.Osteoprotegerin and sclerostin in chronic kidney disease prior to dialysis: potential partners in vascular calcifications. Nephrol Dial Transplant. 2015; 30(8): 1345-1356. doi: 10.1093/ndt/gfv081Kuipers AL, Miljkovic I, Carr JJ et al. Association of circulating sclerostin with vascular calcification in Afro-Caribbean men. Atherosclerosis. 2015; 239(1): 218-223. doi: 10.1016/j.atherosclerosis.2015.01.010Kuipers AL, Miljkovic I, Carr JJ et al. Association of circulating sclerostin with vascular calcification in Afro-Caribbean men. Atherosclerosis. 2015; 239(1): 218-223. doi: 10.1016/j.atherosclerosis.2015.01.010Pelletier S, Confavreux CB, Haesebaert J et al. Serum sclerostin: the missing link in the bone-vessel cross-talk in hemodialysis patients? Osteoporos Int. 2015 Aug; 26(8): 2165-2174. doi: 10.1007/s00198-015-3127-3129Pelletier S, Confavreux CB, Haesebaert J et al. Serum sclerostin: the missing link in the bone-vessel cross-talk in hemodialysis patients? Osteoporos Int. 2015 Aug; 26(8): 2165-2174. doi: 10.1007/s00198-015-3127-3129Claes KJ, Viaene L, Heye S et al. Sclerostin: Another vascular calcification inhibitor? J Clin Endocrinol Metab. 2013; 98(8): 3221-3228. doi: 10.1210/jc.2013-1521Claes KJ, Viaene L, Heye S et al. Sclerostin: Another vascular calcification inhibitor? J Clin Endocrinol Metab. 2013; 98(8): 3221-3228. doi: 10.1210/jc.2013-1521Evenepoel P, Goffin E, Meijers B et al. Sclerostin Serum Levels and Vascular Calcification Progression in Prevalent Renal Transplant Recipients. J Clin Endocrinol Metab. 2015; 100(12): 4669-4676. doi: 10.1210/jc.2015-3056Evenepoel P, Goffin E, Meijers B et al. Sclerostin Serum Levels and Vascular Calcification Progression in Prevalent Renal Transplant Recipients. J Clin Endocrinol Metab. 2015; 100(12): 4669-4676. doi: 10.1210/jc.2015-3056Hampson G, Edwards S, Conroy S et al. The relationship between inhibitors of the Wnt signalling pathway (Dick-kopf-1(DKK1) and sclerostin), bone mineral density, vascular calcification and arterial stiffness in post-menopausal women. Bone. 2013; 56(1): 42-47. doi: 10.1016/j.bone.2013.05.010Hampson G, Edwards S, Conroy S et al. The relationship between inhibitors of the Wnt signalling pathway (Dick-kopf-1(DKK1) and sclerostin), bone mineral density, vascular calcification and arterial stiffness in post-menopausal women. Bone. 2013; 56(1): 42-47. doi: 10.1016/j.bone.2013.05.010Askevold ET, Gullestad L, Nymo S et al. Secreted Frizzled Related Protein 3 in Chronic Heart Failure: Analysis from the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA). PLoS One. 2015; 10(8): e0133970. doi: 10.1371/journal. pone.0133970Askevold ET, Gullestad L, Nymo S et al. Secreted Frizzled Related Protein 3 in Chronic Heart Failure: Analysis from the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA). PLoS One. 2015; 10(8): e0133970. doi: 10.1371/journal. pone.0133970McClung MR, Grauer A, Boonen S et al. Romosozumab in postmenopausal women with low bone mineral density. N Engl J Med. 2014; 370: 412-420. doi: 10.1056/NEJMoa1305224McClung MR, Grauer A, Boonen S et al. Romosozumab in postmenopausal women with low bone mineral density. N Engl J Med. 2014; 370: 412-420. doi: 10.1056/NEJMoa1305224Lanzer P, Boehm M, Sorribas V et al. Medial vascular calcification revisited: review and perspectives. Eur Heart J. 2014; 35(23): 1515-1525. doi: 10.1093/eurheartj/ehu163Lanzer P, Boehm M, Sorribas V et al. Medial vascular calcification revisited: review and perspectives. Eur Heart J. 2014; 35(23): 1515-1525. doi: 10.1093/eurheartj/ehu163Meiting WM, Cameron RC, Cecilia M, Giachelli CM. Vascular Calcification: an Update on Mechanisms and Challenges in Treatment. Calcif Tissue Int. 2013; 93(4): 365-373. doi: 10.1007/ s00223-013-9712-zMeiting WM, Cameron RC, Cecilia M, Giachelli CM. Vascular Calcification: an Update on Mechanisms and Challenges in Treatment. Calcif Tissue Int. 2013; 93(4): 365-373. doi: 10.1007/ s00223-013-9712-z

The authors declare that there are no conflicts of interest present.